Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
- 13 August 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 46 (6), 531-541
- https://doi.org/10.1007/s10928-019-09650-7
Abstract
The effects of contezolid (MRX-I, an oxazolidinone antibacterial agent) on cardiac repolarization were evaluated retrospectively using a population modeling approach in a Phase I study incorporating single ascending dose, multiple ascending dose, and food effect assessments. Linear mixed effect models were used to assess the relationships between MRX-I plasma concentrations and QT/QTc/∆QTc (baseline-adjusted), in which different correction methods for heart rate have been included. The upper bound of the one-sided 95% confidence interval (CI) for predicted ∆∆QTc was < 10 ms (ms) at therapeutic doses of MRX-I. Model performance/suitability was determined using diagnostic evaluations, which indicated rationality of one-stage concentration-QT model, as well as C-QT model suggested by Garnett et al. The finding demonstrated that MRX-I may have no clinical effects on the QT interval. Concentration-QT model may be an alternative to conventional thorough QT studies.Keywords
Funding Information
- The Major Research and Development Project of Innovative Drugs, Ministry of Science and Technology of China (2017ZX09304005)
This publication has 15 references indexed in Scilit:
- QT Assessment in Early Drug Development: The Long and the Short of ItInternational Journal of Molecular Sciences, 2019
- In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2018
- Scientific white paper on concentration-QTc modelingJournal of Pharmacokinetics and Pharmacodynamics, 2017
- Population pharmacokinetics of moxifloxacin and its concentration–QT interval relationship modeling in Chinese healthy volunteersActa Pharmacologica Sinica, 2017
- QT interval prolongation and the risk of torsades de pointes: essentials for cliniciansCurrent Medical Research and Opinion, 2013
- Lack of an Effect of Standard and Supratherapeutic Doses of Linezolid on QTc Interval ProlongationAntimicrobial Agents and Chemotherapy, 2011
- Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects, Dixon et al. 2008; request for publication of PR interval dataBritish Journal of Clinical Pharmacology, 2010
- Concentration‐QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory ReviewThe Journal of Clinical Pharmacology, 2008
- Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongationThe AAPS Journal, 2005
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981